AI Article Synopsis
- A 64-year-old man with advanced lung adenocarcinoma and a KRAS mutation was treated with immune checkpoint inhibitors and later started on sotorasib.
- After one month on sotorasib, he developed severe anemia, indicated by low serum hemoglobin levels, high erythropoietin levels, and low reticulocyte counts.
- Bone marrow tests showed pure red cell aplasia, leading to the conclusion that sotorasib was the likely cause of the anemia after it improved upon stopping the medication.
Article Abstract
We herein report a 64-year-old man with KRAS-mutated advanced lung adenocarcinoma previously treated with immune checkpoint inhibitors (ICIs). One month after starting second-line sotorasib treatment, the patient experienced a progressive decline in serum hemoglobin levels. Anemia was accompanied by markedly elevated serum erythropoietin levels and decreased reticulocyte levels. Bone marrow aspiration revealed pure red cell aplasia. No secondary causes other than medication use were identified. Suspected causative drugs were sotorasib and ICIs. Discontinuation of sotorasib for one week improved his anemia; therefore, the causative drug was identified as sotorasib.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2169/internalmedicine.3961-24 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!